No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

Vorapaxar is a first‐in‐class antagonist of the protease‐activated receptor‐1, the primary thrombin receptor on human platelets, which mediates the downstream effects of thrombin in hemostasis and thrombosis. Prasugrel is a platelet inhibitor that acts as a P2Y12 receptor antagonist through an activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Matt S., Kosoglou, Teddy, Statkevich, Paul, Li, Jing, Rotonda, Jennifer, Meehan, Alan G., Cutler, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811915/
https://www.ncbi.nlm.nih.gov/pubmed/28403576
http://dx.doi.org/10.1002/cpdd.354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811915/
https://www.ncbi.nlm.nih.gov/pubmed/28403576
http://dx.doi.org/10.1002/cpdd.354

Ejemplares similares